Who are Enanta Pharmaceuticals, Inc.'s main suppliers?

Enanta Pharmaceuticals, Inc. (ENTA) key suppliers include: ABBVIE-INC. View the full supplier network at chainsifter.com/chain/ENTA.

Who are Enanta Pharmaceuticals, Inc.'s major customers?

Enanta Pharmaceuticals, Inc. (ENTA) key customers include: ABBVIE-INC, OMERS, Abbott Laboratories, Abbott Laboratories, CAPITAL-RESOURCES. View the full customer network at chainsifter.com/chain/ENTA.

What sector is Enanta Pharmaceuticals, Inc. in?

Enanta Pharmaceuticals, Inc. (ENTA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Enanta Pharmaceuticals, Inc. (ENTA) Suppliers & Customers

1Suppliers

5Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Enanta Pharmaceuticals, Inc. (ENTA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

9Total relationships

2Distinct source URLs

8High confidence

0.873Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Enanta Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ABBVIE-INC	ABBVIE-INC	90%	Under the agreement, we have granted AbbVie an exclusive, worldwide, royalty-bearing license, including a right to grant sublicenses, to specified intellectual property, including several issued U.S.…

Enanta Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
ABBVIE-INC	ABBVIE-INC	92%	AbbVie is responsible for and has funded all costs associated with the development, manufacturing and commercialization of paritaprevir, glecaprevir and any other compounds under this agreement.
OMERS	OMERS	92%	In April 2023, the Company entered into a royalty sale agreement with an affiliate of OMERS, pursuant to which the Company was paid a $ 200,000 cash purchase price in exchange for 54.5 % of future qu…
ABT	Abbott Laboratories	90%	We entered into a Collaborative Development and License Agreement with Abbott Laboratories in November 2006 to develop and commercialize HCV NS3 and NS3/4A protease inhibitors.
ABT	Abbott Laboratories	90%	Reciprocal relationship from ABT graph: Reciprocal relationship from ENTA graph: We entered into a Collaborative Development and License Agreement with Abbott Laboratories in November 2006 to develop…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	research and development expenses will fluctuate from period to period as we advance our research and development programs. However, in the next 12 months, we expect a reduction in our external resea…

Enanta Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ENTA-DEBT	Debt stack $186.6M	90%	Market cache reports total debt of $186.6M.
ENTA-DEBT-9316	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2013-09-30.

Enanta Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
ENTA-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 133 tracked holders.

Enanta Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
NSPR	InspireMD, Inc.	100.00	2
MTLS	Materialise NV	100.00	2
GIFLF	Grifols, S.A.	100.00	2
IINN	Inspira Technologies Oxy B.H.N. Ltd.	100.00	2
NBP	NovaBridge Biosciences	100.00	2
NVS	Novartis AG	100.00	2
IVA	Inventiva S.A.	100.00	2
GCTK	GlucoTrack, Inc.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
ITGR	Integer Holdings Corporation	100.00	2
ALVO	Alvotech	100.00	2
AORT	Artivion, Inc.	100.00	2
GRFS	Grifols, S.A.	100.00	2
PSNL	Personalis, Inc.	100.00	2
FLGT	Fulgent Genetics, Inc.	100.00	2
GRAL	GRAIL, Inc.	100.00	2
GIKLY	Grifols, S.A.	100.00	2
EXAS	Exact Sciences Corp	100.00	2
GIFOF	Grifols, S.A.	100.00	2
NVEC	NVE Corporation	100.00	2

Enanta Pharmaceuticals, Inc. Supply Chain